Key takeaways for Maryland
- • Insulin resistance is not a labeled FDA indication for any GLP-1.
- • Improvements typically substantial (30-50% HOMA-IR reduction).
- • Treat via parent diagnosis (obesity, PCOS, T2D, prediabetes).
- • Maryland Medicaid (HealthChoice) coverage rules apply for Insulin Resistance patients in Maryland — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Insulin Resistance
There is no FDA indication for insulin resistance as a standalone diagnosis — it is a physiological state, not a labeled disease. GLP-1 therapy improves insulin sensitivity through weight loss, slowed gastric emptying, glucagon suppression, and beta-cell function preservation. Evidence grade: B. Patients with insulin resistance are typically treated via comorbid diagnoses (obesity, prediabetes, PCOS, T2D). HOMA-IR scores typically improve 30-50% with sustained semaglutide or tirzepatide therapy.
Maryland-specific context
Maryland has telehealth access concentrated in Baltimore, Frederick, Rockville metros, with additional reach to Gaithersburg and Bowie. Johns Hopkins Medicine, University of Maryland Medical System is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at health.maryland.gov.
Marylandtelehealth & pricing rules
- • Maryland requires a live video consultation before a GLP-1 prescription.
- • Maryland allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Maryland: ~$318/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.